ESR1 and breast carcinoma: The current study therefore evaluated the combinatorial potential of SM6Met to act synergistically with (2)-4-hydroxytamoxifen (4-OH-Tam), the active metabolite of tamoxifen, in preventing ER+ breast cancer proliferation.